Top

Supportive Care in Cancer

Published in:

01-01-2007 | Original Article

The emerging role of cannabinoid neuromodulators in symptom management

Authors: Mellar Davis, Vincent Maida, Paul Daeninck, Joseph Pergolizzi

Published in: Supportive Care in Cancer | Issue 1/2007

Abstract

Introduction

The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy.

Discussion

The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain.

Summary

The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.

Abrahm JL (2005) A physician’s guide to pain and symptom management in cancer patients, 2nd edn. Johns Hopkins University Press, Baltimore, MD

Andrews PL, Naylor RJ, Joss RA (1998) Neuropharmacology of emesis and its relevance to anti-emetic therapy. Consensus and controversies. Support Care Cancer 6:197–203CrossRefPubMed

Cichewicz DL (2004) Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74:1317–1324CrossRefPubMed

Cloning the receptor (Autumn 2005) O’Shaughnessy’s Journal of the California Cannabis Medical Research Group. Available at: http://www.ccrmg.org

Dronabinol (Marinol®) (2005) Prescribing information. Solvay Pharmaceuticals, Marietta, GA

Green S, Newman Z, Nordquist S (2005) Pharmacological evidence for cannabinoid receptors in glutamatergic synapses at the crayfish neuromuscular junction. Pioneering Neuroscience 6:55–61

Hohmann AG, Briley EM, Herkenham M (1999) Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 822:17–25CrossRefPubMed

Kalant H (2001) Medicinal use of cannabis: history and current status. Pain Res Manag 6:80–91PubMed

Khatcheressian J, Cassel JB, Lyckholm L, Coyne P, Hagenmueller A, Smith TJ (2005) Improving palliative and supportive care in cancer patients. Oncology (Williston Park) 19:1365–1376

10.

Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2006. Available at: http://www.asco.org

11.

Lynch ME (2005) Preclinical science regarding cannabinoids as analgesics: an overview. Pain Res Manag 10(suppl A):7A–14APubMed

12.

Nabilone (Cesamet™) (2006) Prescribing information. Valeant Pharmaceuticals International, San Diego, CA

13.

Nahas G, Harvey DJ, Sutin K et al (2002) A molecular basis of the therapeutic and psychoactive properties of cannabis (Δ⁹-tetrahydrocannabinol). Prog Neuropsychopharmacol Biol Psychiatry 26:721–730CrossRefPubMed

14.

Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098CrossRefPubMed

15.

Russo EB (2002) The role of cannabis and cannabinoids in pain management. In: Weiner RS (ed). Pain management: a practical guide for clinicians, 6th edn. CRC Press, Boca Raton, FL, pp 357–375

16.

Roberts JD, Gennings C, Shih M (2006) Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 530:54–58CrossRefPubMed

17.

Sativex® oromucosal spray (2006). Available at: http://www.gwpharm.com/sativex.asp

18.

Strangman NM, Walker JM (1999) Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol 82:472–477PubMed

19.

Svendsen KB, Jensen TS, Bach FW (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329:253CrossRefPubMed

20.

Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy-induced nausea and vomiting: quantitative systematic review. BMJ 323:16–21CrossRefPubMed

21.

Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, Tsou K (1999) The neurobiology of cannabinoid analgesia. Life Sci 65:665–673CrossRefPubMed

22.

Walsh D, Nelson KA, Mahmoud FA (2003) Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 11:137–143CrossRefPubMed

23.

Wiser W, Berger A (2005) Practical management of chemotherapy-induced nausea and vomiting. Oncology (Williston Park) 19:637–645

24.

World Health Organization (April 3, 2003) Global cancer rates could increase by 50% to 15 million by 2020. Available at: http://www.who.int/mediacentre/news/releases/2003/pr27/en/index.html

Title: The emerging role of cannabinoid neuromodulators in symptom management
Authors: Mellar Davis
Vincent Maida
Paul Daeninck
Joseph Pergolizzi
Publication date: 01-01-2007
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 1/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-006-0180-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Discussion

Summary

Please log in to get access to this content

Other articles of this Issue 1/2007

Feasibility of integrated home/hospital physiotherapeutic support for children with cancer

The cost of chemotherapy-induced nausea and vomiting in Italy

Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication

Clinical validity of the Japanese version of the Functional Assessment of Cancer Therapy-Anemia Scale

Global quality of life and its potential predictors in breast cancer patients: an exploratory study

The effects of age and emotional acceptance on distress among breast cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer